Literature DB >> 8399984

Angiotensin-II-and endothelin-induced protein phosphorylation in cultured vascular smooth muscle cells.

T Tsuda1, K K Griendling, J D Ollerenshaw, B Lassègue, R W Alexander.   

Abstract

In cultured vascular smooth muscle cells, angiotensin II and endothelin stimulate a variety of intracellular signals, including generation of inositol trisphosphate and diacylglycerol, mobilization of intracellular calcium, and activation of protein kinase C. These latter two events have been shown to mediate the phosphorylation of numerous proteins, but these substrates and the specific pathways mediating their phosphorylation have not been identified in vascular smooth muscle. Angiotensin II (100 nM, 10 min) induced a characteristic pattern of protein phosphorylation, which included the phosphorylation of many proteins, ranging in molecular mass from 20 to 76 kD. Three of these proteins have been identified as vimentin (M(r) 57,000), a specific protein kinase C substrate (M(r) 76,000) and the myosin light chain (M(r) 20,000). The 76-kD protein was one of the most highly phosphorylated proteins after agonist treatment. Endothelin-1 produced an identical pattern of phosphorylation. Five of these substrates were also phosphorylated by phorbol-12-myristate-13-acetate, and 5 were also phosphorylated after treatment with ionomycin. In general, the protein-kinase-C-dependent phosphorylations were sustained, while those mediated by calcium were rapid. Since these experiments were performed in cultured, phenotypically modulated cells stimulated with agents that promote cellular hypertrophy or hyperplasia, this pattern of phosphorylation may be representative of that seen during the growth response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399984     DOI: 10.1159/000159002

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  1 in total

1.  Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance.

Authors:  F Terzi; D Henrion; E Colucci-Guyon; P Federici; C Babinet; B I Levy; P Briand; G Friedlander
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.